Abivax Announces Launch of Public Offering

Abivax Announces Launch of Public Offering

PARIS, France, July 23, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today the launch of an approximately $400 million underwritten public offering (representing approximately €340 million) consisting of a public offering of its American Depositary Shares (“ADSs”), each representing one ordinary share, €0.01 nominal value per share (each an “Ordinary Share”), of the Company in the United States (the “Offering”). In connection with the Offering, the Company intends to grant the underwriters for the Offering a 30-day option to purchase additional ADSs, in an amount of up to 15% of the total number of ADSs proposed to be sold in the Offering, on the same terms and conditions.

Read more at globenewswire.com